论文部分内容阅读
目的:了解辛伐他汀对老年冠心病患者降脂治疗的效果和安全性。方法:选择老年冠心病患者58例,给予辛伐他汀20 mg/d治疗。按照预定的总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)达标水平调整药物的剂量,分别于用药前,用药后4,12周测定TC,TG,LDL-c,HDL-C,随访3个月。结果:治疗后TC、LDL-C和甘油三酯(TG)较治疗前明显下降(P<0.05),随访结束时,36%的患者服用辛伐他汀20 mg/d保持TC<4.7 mmol/L和LDL-C<2.6 mmol/L,64%的患者服用辛伐他汀10mg/d保持TC<4.2 mmol/L和LDL-C<2.1 mmol/L无明显不良反应发生。结论:辛伐他汀对冠心病患者降脂治疗效果确切,安全性良好。
Objective: To understand the effect and safety of simvastatin on lipid-lowering therapy in elderly patients with coronary heart disease. Methods: 58 elderly patients with coronary heart disease were selected and given simvastatin 20 mg / d. The dosage of TC, TG, LDL-c and HDL-C were measured before and at 4 and 12 weeks after treatment according to the predetermined level of total cholesterol (TC) and low density lipoprotein cholesterol (LDL- Follow up for 3 months. Results: The levels of TC, LDL-C and triglyceride decreased significantly after treatment (P <0.05). At the end of follow-up, 36% of patients took simvastatin 20 mg / d for TC <4.7 mmol / L And LDL-C <2.6 mmol / L, 64% of patients taking simvastatin 10 mg / d with TC <4.2 mmol / L and LDL-C <2.1 mmol / L without adverse reactions. Conclusion: Simvastatin has definite effect on lipid lowering in patients with coronary heart disease and its safety is good.